60 days until the J.P. Morgan 38th annual Healthcare Conference (#JPM2020). Removing the upcoming holidays and weekends, we’re talking 36 business days. Are you ready? J.P. Morgan 38th Annual Healthcare Conference (JPM 2020) will take … Read More
Slowly, but ever so surely, the diabetes treatment landscape is evolving along two continuums. The first is the world of glucose management, in which innovation is the integration of therapeutic products with digital, technology, and … Read More
Diabetes, once considered a disease of the pancreas, is now understood to be a complex, multi-hormonal disease leading to devastating clinical & financial outcomes. Twenty years of attending A.D.A. scientific congress provides a unique, historical … Read More
Boehringer Ingelheim & Eli Lilly and Evoke Health for Jardiance Jardiance Asks: Consumer Campaign An authentic approach successfully engaged type 2 diabetes patients who were unaware of and unreceptive to learning about the link … Read More
INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to update … Read More
Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral version that could pose another threat to rivals in the field. In a new phase … Read More
The U.S. Food and Drug Administration has approved erenumab (Aimovig™, Amgen and Novartis), a first-in-class calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraine in adults. Erenumab consistently demonstrated an ability to reduce monthly … Read More
